If you’re researching “how much do breast implants cost,” chances are you are imagining all the benefits they offer. Breast augmentation is the top cosmetic plastic surgery procedure performed in the United States for a reason. Breast augmentations have a high rate of patient satisfaction according to research. In a study published in the May 2013 issue of Plastic and Reconstructive Surgery, researchers gathered information from 225 women after their breast augmentations. The study revealed that 91.1% of women felt improved self-esteem, 64.3% had an improved quality of life, and 98.7% would repeat the surgery. But there is another side to breast implants, one you should know about before scheduling your plastic surgery consultation. While the initial costs and satisfaction rates are similar between implant types, the long-term maintenance costs and emotional toll differs in important ways. Silicone gel breast implants carry a high rate of certain complications and an increased anxiety when compared to the newest breast implant on the market, IDEAL IMPLANT® Structured Breast Implants.
Transaxillary: an incision made to the axilla (armpit), from which the dissection tunnels medially, to emplace the implants, either bluntly or with an endoscope (illuminated video microcamera), without producing visible scars on the breast proper; yet, it is likelier to produce inferior asymmetry of the implant-device position. Therefore, surgical revision of transaxillary emplaced breast implants usually requires either an IMF incision or a periareolar incision.
The FDA has identified that breast implants may be associated with a rare form of cancer called anaplastic large-cell lymphoma, believed to be associated with chronic bacterial inflammation. Similar ALCL phenomena have been seen with other types of medical implants including vascular access ports, orthopedic hip implants, and jaw (TMJ) implants. As of February 1, 2017, the FDA has received a total of 359 medical device reports of breast-implant-associated ALCL (BIALCL), including 9 deaths. Most cases of breast implant-associated ALCL had implants in for many years prior to the condition, and are usually treated successfully by simple removal of the implant and the capsule surrounding the implant without the need for chemotherapy if no evidence of systemic disease exists. If women with implants present with delayed swelling or fluid collection, cytologic studies and test for a marker "CD30" are suggested. The American Society of Plastic Surgery (ASPS) states, "CD30 is the main diagnostic test that must be performed on the seroma fluid as routine pathology or H&E staining can frequently miss the diagnosis."  Diagnosis and treatment of breast implant associated ALCL now follows standardized guidelines established by the National Comprehensive Cancer Network.